Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Mid-year is when income-focused investors tend to take a hard look at their portfolios. With the second half of 2026 ahead, retirees and near-retirees are leaning into reliable dividend payers that can keep checks coming through any summer volatility. The three names below combine long dividend histories, defensive cash flows, and recent raises, exactly the ... 3 Dividend Stocks Built for Retirement to Buy in June
Over the last 7 days, the United States market has dropped 3.3%, yet it remains up 22% over the past year with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying stocks that are potentially priced below their intrinsic value can offer opportunities for investors seeking long-term growth, such as Coastal Financial and two other noteworthy companies.
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
Over the last 7 days, the United States market has dropped 3.3%, yet it remains up by 22% over the past year, with earnings expected to grow by 17% annually in the coming years. In this fluctuating environment, identifying stocks that may be trading at a discount can offer investors opportunities to capitalize on potential value gains.
Over the last 7 days, the United States market has experienced a 2.7% drop, though it has risen by 23% over the past year, with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying undervalued stocks can present opportunities for investors seeking to capitalize on potential growth and favorable market estimates.
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.
Over the last 7 days, the United States market has experienced a 2.7% decline, yet it remains up by 23% over the past year with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be below their fair value can present opportunities for investors looking to capitalize on potential growth amid current market fluctuations.
Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
A retiree’s $40,000 dividend income stream sounds modest next to a neighbor’s $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The ... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000
ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.
Over the last 7 days, the United States market has experienced a 2.5% decline, though it has seen a significant rise of 23% over the past year, with earnings projected to grow by 17% annually. In this context, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets in an evolving market landscape.
Bristol Myers Squibb (NYSE:BMY) is the headline pharma name dividend hunters keep circling, drawn in by a 4.37% yield and a forward P/E of 9 that screams cheap. But the underlying numbers tell a different story. That low multiple is cheap for a reason. Bristol Myers is running headfirst into a generic cliff that the ... Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now
AbbVie (ABBV) is back in focus after a cluster of regulatory decisions, including FDA approval of DECNUPAZ for a rare blood cancer and European green lights for AQUIPTA and new VENCLYXTO combinations. See our latest analysis for AbbVie. The recent approvals have coincided with building momentum in the stock, with a 1 month share price return of 10.83% and a 1 year total shareholder return of 23.60%, while the 3 year total shareholder return sits at 83.11%. If these developments caught your...
A 63-year-old retiree with $400,000 parked in the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) likely picked it for the 100-stock screen and the reliable income stream. The top 10 positions now make up 41% of the fund, which means roughly $164,000 of that nest egg sits in ten names. For a fund managing $94 billion, ... SCHD’s $85 Billion Strategy Now Concentrates 41 Percent of Your Money in Just Ten Stocks
Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.
AbbVie Inc. (NYSE:ABBV) is one of the best cheap stocks to buy for beginners. AbbVie Inc. (NYSE:ABBV) announced on June 2 that the European Commission approved AQUIPTA® for the acute treatment of migraine in adults with or without aura, to be taken as needed. Management stated that the approval marks the second indication for AQUIPTA in […]
AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.
The United States market has shown a remarkable 26% increase over the past year, despite remaining flat over the last week, with expectations for earnings to grow by 16% annually in the coming years. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities that align with these growth prospects and current market stability.
In the last week, the United States market has stayed flat, yet it has experienced a significant 26% increase over the past year with earnings forecasted to grow by 16% annually. In such a robust environment, identifying stocks that are estimated to be below their intrinsic value can offer investors potential opportunities for growth and value appreciation.
Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.
In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.
AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.
The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
